Co-Diagnostics $CODX: PCR, Regulatory Progress and the Funding Test

01 Three paths from a platform to a business

A constructive scenario begins with authorized products and repeat customer demand. The regulatory process would produce a useful commercial scope, the company would execute manufacturing and distribution, and customers would use sufficient consumables to support a growing revenue stream. Environmental testing would provide an additional source of recurring use rather than remaining a collection of isolated installations.

That scenario depends on several links working together. Instrument placement has to lead to actual testing. Actual testing has to lead to paid consumable demand. Demand has to produce enough gross profit to support service, distribution and the company’s operating structure. A weakness in one link can substantially reduce the value of the others.

Funding is part of the constructive scenario. Co-Diagnostics would need resources to complete regulatory and commercial work without weakening the per-share opportunity excessively. Product success and financing terms are connected: a credible commercial milestone may improve access to capital, while more difficult financing can slow implementation even when the product remains useful.

A middle scenario involves progress with a slower commercial ramp. Regulatory work could advance while customers take longer to adopt the platform. Environmental installations could continue but generate a modest consumable contribution. International programs could remain useful development routes without becoming significant near-term revenue sources.

That middle scenario can be scientifically and operationally respectable while still challenging for shareholders. Operating expenses continue during the transition. Financing may be needed before recurring demand reaches a useful scale. The cost of the delay, and the ownership issued to fund it, influence the resulting equity economics.

A contrary scenario combines a delayed or narrowed regulatory path with insufficient commercial contribution. The company could face requests for additional work, a more limited authorized setting or difficulty building repeat use. Weak revenues would then increase dependence on outside capital and operating reductions.

The contrary scenario does not require every program to fail. A company can have several plausible opportunities while lacking the capital to convert them into a durable business. Commercial concentration, implementation costs, customer budget cycles and funding terms can be consequential even when the underlying technology remains scientifically credible.

These scenarios identify business combinations rather than share-price outcomes. Evidence that would distinguish them includes agency decisions, the scope of authorized use, recurring test demand, gross profit, expense discipline and completed financing. A favorable headline has more value when it improves several of those variables together.

02 The business model: technology, instrument and consumable

Co-Diagnostics develops, manufactures and sells molecular testing reagents and related technology. Its current activities span diagnostic development, PCR instruments, environmental monitoring and international initiatives. The quarterly filing provides the corporate and financial foundation for these activities. Business description

A platform business can contain several economic layers. Technology and intellectual property support the product. Instruments enable users to perform tests. Consumables create recurring transactions. Software, training and support help make the workflow reliable. Each layer has a different contribution to revenue and cost.

The recurring layer is particularly important. An instrument may create a relationship with a customer, but its economic value depends on the amount and duration of subsequent use. A placement with limited testing can have much less value than an installation with stable consumable demand.

The business also has to define who pays and why. A clinical customer may value a result that changes patient management within a useful timeframe. An environmental customer may value surveillance that supports a monitoring or control program. These are different buying decisions with different regulatory requirements and budget structures.

Platform breadth can create optionality, but it can also create complexity. Developing several tests or markets requires resources and organizational focus. A useful strategy would select opportunities that share enough technology and operational infrastructure to improve the economics of the portfolio.

The core business question is therefore the conversion from development to repeated use. The number of applications creates a list of possibilities. The company’s revenue, customer behavior and funding position show how far those possibilities have progressed toward a sustainable enterprise.

03 Molecular testing: performance in a real workflow

PCR detects and amplifies genetic material to support molecular analysis. For a company developing PCR products, the commercial objective is not simply to demonstrate amplification in a laboratory. It is to deliver reliable results in the intended workflow with appropriate controls, usability and economics.

Analytical performance and clinical performance answer different questions. Analytical work examines features such as detection, interference, reproducibility and other properties of the test. Clinical evaluation examines how the test performs with relevant specimens and populations. Both matter, but neither can be replaced by a broad statement that the technology is sensitive.

The sample is part of the system. Collection, handling, preparation and storage can influence the final result. A product designed for decentralized use must account for the skills and conditions available in that setting. Simplifying those steps can be commercially useful, provided that reliability is preserved.

Controls are another part of the workflow. Users need a way to identify invalid or questionable runs and to understand the actions required. A system that produces a rapid result but leaves uncertainty about the validity of the test can create additional work instead of reducing it.

The useful economic unit is often the cost per actionable result, rather than the nominal price of a test. Repeat testing, invalid runs, labor, maintenance, consumables and turnaround all affect that cost. The customer’s decision may depend on the combined workflow rather than the headline speed or instrument price.

For CODX, the opportunity is to create a platform whose scientific capabilities remain useful outside the development laboratory. The evidence needed for that opportunity includes performance, authorization, usability, repeat demand and the costs of delivering the result.

04 Point-of-care PCR: the promise and the implementation burden

Point-of-care molecular testing seeks to place useful testing closer to the decision it informs. A shorter workflow can be valuable when the result changes care, reduces uncertainty or avoids the delay of sending a sample elsewhere. The size of that benefit depends on the specific test and clinical setting.

A decentralized system must still deliver reliable results. The operator may have different training from a centralized laboratory technician. Space, equipment, cleaning, sample handling and quality processes may differ. Product design and instructions need to support those real conditions.

Ease of use is therefore a substantive product feature. It can reduce the labor and training required for implementation. It can also influence the level of regulatory scrutiny associated with the intended setting. A product’s authorized use and the conditions attached to it define the practical commercial scope.

Testing speed is valuable only when it fits the clinical decision. A result obtained quickly but after the relevant decision has already been made may add less value. Conversely, a test that fits an established pathway can become useful even without being the fastest system available.

The instrument must also be supported. Customers may need training, service, consumable supply and a response to errors or downtime. A small company has to build or obtain that infrastructure. The cost and reliability of support can influence both adoption and margins.

This creates an important distinction between a product demonstration and a commercial rollout. Demonstrating a workflow is a development step. Reproducing it across customers, with service and supply at scale, is an operating challenge. The value of the platform depends on its ability to make that transition.

05 FDA review and CLIA waiver: distinct decisions

Co-Diagnostics announced submission of a 510(k) premarket notification for its Flu A/B and RSV test. The Q2 results also described a concurrent CLIA Waiver by Application. These are related to commercialization, but they concern distinct questions. Regulatory announcement

The respiratory filing is not the company’s first attempt to take Co-Dx PCR Pro through FDA review. According to the Q2 Form 10-Q, Co-Diagnostics completed a 510(k) application in June 2024 for the Co-Dx PCR Pro instrument, the Co-Dx PCR COVID-19 Test and the Co-Dx PCR mobile app for over-the-counter use. Following engagement with the FDA during that review, the company voluntarily withdrew the submission after discussions regarding the analytical approach for detecting potential degradation of a test component over its intended shelf life. The company states that it believes the matter could have been addressed through additional development and clinical validation, but management concluded that the capital and time needed to resubmit the COVID-19 test would be better deployed on the Flu A/B and RSV multiplex test, which also allowed it to incorporate more recent platform developments. In our reading, that history does not describe a problem with the current test; it does show that component stability and shelf life are among the questions a review can raise, and that a review can end without an agency decision when a company chooses to change course. Q2 Form 10-Q, MD&A

A 510(k) review concerns whether the submitted device meets the relevant clearance standard for its proposed use. A CLIA waiver concerns the complexity and conditions under which testing can be performed in waived settings. A product’s eventual market depends on the scope and conditions of the applicable decisions.

The important milestone is the agency’s decision and its terms. Clearance, any waiver and their timing depend on the agency review. An agency can ask for additional information, and the company’s response may involve further work.

The commercial implications of a clearance can vary. An authorized claim may be narrower than the range of applications discussed during development. The permitted sample, patient population, setting and instructions matter. Sales plans need to fit that actual scope.

A waiver can affect access to decentralized settings, but it is not a substitute for the performance and use requirements of the device. Customers still need appropriate procedures and compliance with the conditions of use. Simplicity is a meaningful objective because it helps a product fit those settings reliably.

For shareholders, regulatory progress has value when it opens an executable commercial path. The path still requires production, distribution, support and demand. Agency decisions remove particular uncertainties; they do not remove every business risk.

06 Clinical evidence: what a study needs to show

The August 6 company announcement describes more than 1,400 symptomatic patients across nine U.S. clinical sites, together with 27 analytical studies and more than 10,000 PCR tests, including multicenter reproducibility work. These figures quantify the development work supporting submission. They do not provide a substitute for the agency’s evaluation or for the detailed performance results needed to assess each intended use. Submission announcement

The Q2 release described clinical and analytical work supporting the respiratory submission, including a multi-site clinical study and a substantial analytical testing program. The significance of those activities depends on the study design and the results supporting the intended use. Development summary

A clinical evaluation should reflect the specimens and circumstances in which the product is expected to be used. The population, reference method, prevalence and handling of invalid or discordant results all influence interpretation. A large number of test runs is useful, but the design determines which questions that work answers.

Analytical testing has a different role. It can characterize performance under controlled conditions, potential interference, reproducibility and the boundaries of the system. These results support product reliability, but clinical effectiveness in the intended setting requires its own evidence.

The distribution of samples matters. A study with many negative samples and relatively few positives can have different strengths from one with substantial representation across each target pathogen. Aggregate performance should therefore be considered alongside target-specific results and the uncertainty surrounding them.

Workflow evidence also matters. The system’s intended operators, sample steps and error handling should be consistent with the commercial plan. A product can perform well under expert supervision while requiring further work to achieve reliable use by the intended customer.

The value of a successful evidence package is that it supports both review and implementation. It helps define the product’s authorized role and gives customers a reason to trust the result. That is the foundation of repeat use, rather than a separate technical detail.

07 Respiratory testing: usefulness depends on the care pathway

The submitted test targets influenza A, influenza B and RSV. Multiplex testing can be useful when several pathogens produce overlapping symptoms and the distinctions influence management, infection control or other decisions. The value of a result depends on the setting and the action available to the user.

Seasonality affects demand. A platform serving respiratory testing may experience changes in testing volume across the year. Commercial planning needs to account for consumable availability, inventory and the customer’s expected workflow during higher-demand periods.

A customer’s decision may also involve reimbursement and budget. Clinical usefulness is necessary, but a clinic or provider has to understand who pays, how the test fits existing processes and whether the combined cost is acceptable. An authorized product needs a viable economic role as well as a clinical one.

Competition can come from several directions: centralized laboratories, existing molecular systems, other rapid tests and current clinical practice. The relevant comparison is the total workflow, including the speed, information, reliability and cost associated with each option.

CODX’s commercial test would be evidence that the platform earns a repeat place in that workflow. The first sale or demonstration creates an opportunity. Stable use across customers, with reasonable service and supply economics, would provide stronger evidence of a durable business.

08 Vector Smart: environmental monitoring is a separate use case

The company has announced Vector Smart laboratory installations, including new facilities in Florida, a first international deployment completed in September through an order from an overseas U.S. Air Force base, and the October order for a Ute Indian Tribe laboratory. The Florida announcement reports completed installations; the October 7 update describes the Air Force milestone as a deployment through the company’s first order from the U.S. Air Force, without separately describing a full laboratory installation; the Ute announcement reports an order for a future installation. These are different operating milestones in vector and environmental monitoring. Florida installations · USAF deployment · Ute laboratory order

The company has also published two measures of the footprint. The Q2 results reported four new mosquito abatement district laboratory installations completed during the quarter and a Vector Smart customer footprint covering 21 U.S. states. The October 7 update states that, since launch, Vector Smart has served 40 customers across 21 U.S. states, and lists new full laboratory installations in Florida and Indiana and an additional independent evaluation of the Vector Smart VZDC assay by a state public health laboratory. Forty customers served since launch is a cumulative count: the releases do not say how many are active, how many reorder consumables or how much revenue each produces, so the figure measures reach rather than recurring demand. Q2 results · October 7 update

Environmental surveillance can support decisions about monitoring and control programs. Its customer value differs from that of a diagnostic test used directly for patient care. The purchasing organization, sample type, purpose and regulatory context may also differ.

This separation is important when interpreting company news. An environmental installation can demonstrate demand and operational capability without proving clearance for a human clinical test. A diagnostic regulatory decision can advance one product without determining the economics of the environmental business.

Installations are nevertheless useful operating evidence. They show that a customer has moved beyond an expression of interest toward implementing a laboratory or system. The next economic question is the frequency and duration of actual use and the contribution from recurring test supply.

Customer breadth can make the business more resilient, but the quality of demand matters as much as the number of locations. Small installations with limited recurring use may have different economics from a smaller group of customers with stable testing programs. Geographic expansion needs to be connected with revenue and retention.

Vector Smart should therefore be considered as a potential recurring business line with its own evidence path. Implementation, demand, consumable economics and customer budgets will determine its financial contribution.

09 Installed base economics: utilization is the missing bridge

An installed base can create recurring revenue opportunities, but the relationship between a placement and economic value depends on utilization. A system used frequently over a long period can support substantial consumable demand. A system used intermittently may provide a smaller contribution even if the installation is technically successful.

Utilization depends on the customer’s purpose and budget. A surveillance program may test according to a defined schedule or in response to disease activity. A clinical customer may test based on patient volume and the role of the result in care. Those patterns can produce different revenue visibility.

Consumable margins also matter. Revenue can grow while the cost of production, shipping, support and distribution limits gross profit. A useful installed-base model needs to include those costs rather than assuming every additional test is equally profitable.

Customer retention is another variable. Continued use over time can improve the economics of the initial sales and implementation effort. Churn or a shift to another system can reduce the value of the placement and increase the burden of acquiring replacement customers.

The most informative evidence would connect the installed footprint with recurring demand and financial contribution. That could involve consumable revenue, repeat orders, retention or other appropriate operating measures. Installations are a starting point; the bridge to a durable business is the continued use they generate.

10 India and tuberculosis: development before revenue assumptions

The company announced clinical studies in India for a tuberculosis test on its PCR platform, through its CoSara joint venture. That creates a disease-specific development route with potential relevance to decentralized molecular testing. The clinical work and the commercial path need to be assessed separately. July 22 announcement

The relationship with CoSara also runs through the cost line. The Q2 Form 10-Q describes CoSara as one of the company’s equity method investments and states that, under a services agreement, CoSara provides research and development consulting and support services pertaining to the ongoing development of the Co-Dx PCR platform. Co-Diagnostics recognized $262,129 of expense under that agreement in the second quarter of 2026 and $488,525 in the first half, compared with $182,364 and $422,467 in the corresponding periods of 2025. The joint venture is therefore both a development partner and a provider of services that the listed company pays for. Q2 Form 10-Q, Note 12 and MD&A

A tuberculosis program has its own clinical and operational requirements. The specimens, performance expectations, intended setting and role of the test in patient management determine the evidence needed. Success in a respiratory viral test does not automatically show the performance of a tuberculosis application.

Local regulatory requirements also matter. The authorization of a test in one country does not create an identical commercial scope elsewhere. Manufacturing, distribution and reimbursement can vary. A country-specific plan must fit those conditions.

Affordability and access are central to the customer proposition. A decentralized system can be valuable if it provides a reliable result in a useful setting at an acceptable overall cost. Instrument availability, supply, support and operator requirements can affect that proposition.

A development milestone is therefore an opportunity to generate evidence, rather than a completed revenue stream. Clinical performance, regulatory decisions and customer implementation would determine the next steps. Any economic model should preserve that sequence.

For CODX, the India program may expand the platform’s applications and international relationships. Its contribution will depend on the results and the commercial structure that follows them, including the rights and economics retained by the listed company.

11 Saudi manufacturing: a site is one part of a supply chain

The Q2 release described industrial-site approval and a lease arrangement for a planned manufacturing facility in Saudi Arabia through CoMira Diagnostics. These steps support a localization strategy for the Middle East and North Africa. They are preparatory milestones rather than evidence of a fully operating and profitable manufacturing business. Q2 operational update

The 2025 annual report sets out the structure behind CoMira. The joint venture was formed on October 27, 2025 with Arabian Eagle Manufacturing, a regional manufacturing and distribution company based in Saudi Arabia that the company describes as having been its primary distributor in the Middle East. Co-Diagnostics invested an initial $102,566, representing a 50% ownership interest accounted for under the equity method. The agreement covers Saudi Arabia and 18 other countries across the Middle East and North Africa, and Co-Diagnostics will provide CoMira an exclusive license to use, manufacture and commercialize the licensed intellectual property in the region, including the Co-Dx PCR platform and the company’s existing lab-based PCR products. The Q2 release locates the approved industrial site and the executed lease in Sudair Industrial City. Because CoMira is an equity-method investment, its results enter CODX’s statements as the company’s share of the venture’s profit or loss rather than as consolidated revenue; what regional sales would mean for CODX shareholders also depends on the license and supply arrangements between the parties. 2025 Form 10-K, Business and Note 7 · Q2 Form 10-Q · Q2 results

Manufacturing requires more than a site. Equipment, processes, validation, quality systems, personnel and regulatory requirements all affect readiness. The cost and timing of those steps determine how quickly a plan can become usable capacity.

Capacity itself is also distinct from demand. A facility can be technically capable of producing products without having sufficient orders to operate economically. A commercial plan needs both reliable supply and customers whose use supports the investment.

Localization can offer advantages, including proximity to customers and alignment with local industrial priorities. Those advantages still need to be translated into a viable operating model. The ownership structure, funding responsibilities and economics of the venture matter to the listed company’s shareholders.

The most useful future evidence would identify which products are produced, the applicable authorization, customer demand and the resulting revenue or contribution. A geographic opportunity becomes more concrete as those details emerge.

The Saudi initiative should therefore be considered a development and supply-chain option. Its value depends on successful execution and its connection to a financed commercial opportunity, rather than the size of the region alone.

12 ReadyGo and Ebola: an evaluation collaboration

The September ReadyGo announcement concerns evaluation of blood-based molecular testing at the point of need, beginning with Ebola. It describes a collaboration intended to investigate an application. That scope is important: the work is a development activity, and clinical use requires the appropriate performance evidence and regulatory authorization. Collaboration announcement

Two further disclosures frame that work. A September 15 Form 8-K states that the August material transfer agreement provides ReadyGo sampling materials for feasibility studies, that the evaluation activities are preliminary in nature, and that the agreement does not obligate either party to enter into any development, supply, commercialization or other commercial arrangement. Separately, the Q2 results reported the start of development of a Bundibugyo virus PCR assay, with CoSara providing Bundibugyo virus test kits for analytical studies in India and continuing a pan-Ebola assay strategy, and the completion of a proof-of-concept study evaluating extraction-free plasma-based testing on the Co-Dx PCR platform. These are early development steps; none of them is a regulatory authorization or a procurement contract. September 15 Form 8-K · Q2 results

A blood-based application presents particular sample and workflow questions. Collection, preparation, biosafety and the conditions of use can all influence feasibility. A concept that is scientifically promising needs a complete operational route to become useful in the intended setting.

Outbreak response can create a strong need for reliable testing, but demand may be episodic. A sustainable business needs to consider preparedness, procurement, inventory and the timing of customer budgets. A large public-health need does not automatically create a stable commercial stream.

Partnerships can combine complementary capabilities and reduce some development burdens. They can also introduce dependencies on the partner’s performance, funding or rights. The economic significance depends on the agreed structure and the listed company’s role.

The most meaningful milestones would be defined evaluation results, a clarified development path and the relevant authorization or procurement steps. Each would reduce a particular uncertainty. A collaboration announcement begins that sequence; it does not complete it.

For shareholders, the opportunity is best viewed as another potential application of the platform. Its development value should be considered alongside the resources required and the priority of the company’s nearer commercial and regulatory work.

13 Financial position: the current scale is the central constraint

The reported Q2 revenue base is small compared with operating expenses. That relationship gives the business a very different risk profile from a profitable diagnostic supplier. Development achievements can be meaningful while the company still depends on financing to support its operating plan.

A decline in expenses can improve the position, but the reason and durability of the reduction matter. Some spending can be controlled without materially weakening the business. Other reductions may delay development, limit commercial support or reduce the company’s ability to execute.

Revenue quality is also important. Recurring product demand can provide a stronger basis for planning than one-time transactions or episodic grant income. The business needs to show which activities contribute and how those contributions relate to the cost structure.

Cash is a dated balance rather than a permanent resource. Subsequent financing, spending and obligations can change it. A quarter-end cash figure is useful for understanding the reported period, but it cannot be presented as the amount available indefinitely after that date.

The quarterly filing’s going-concern discussion makes the financing dependency explicit. That discussion concerns conditions and management’s plans; it is neither proof of inevitable failure nor a reason to assume the funding issue is resolved. The relevant evidence is the capital actually obtained and the operating work it can support.

The same filing reports a pending legal matter that belongs in the budget discussion. The company is a defendant in a securities class action claiming that it overstated demand for its Logix Smart COVID-19 test. On July 28, 2026, the parties to the Stadium Capital securities class action in the Southern District of New York entered into a binding term sheet for a proposed settlement under which the defendants will pay, or cause to be paid, an aggregate of $6.5 million into a settlement fund. The proposed settlement contains no admission of wrongdoing or liability; definitive documentation was still being negotiated, and the settlement remains subject to preliminary and final court approval, notice to the class, termination conditions and a final judgment dismissing the action. The filing does not state how the $6.5 million would be divided among the company, its insurers or the other defendants, so the aggregate should not be read as a cash outflow of that size for CODX. Q2 Form 10-Q, Legal Proceedings

A stronger financial position would involve repeat revenue at a scale that improves gross profit and reduces the burden placed on outside capital. Until then, operating progress and financing need to be considered as linked parts of the same business problem.

14 Financing: completed proceeds and program capacity

The October loan carries thirty weekly installments, senior security over substantially all assets, 600,000 commitment shares and variable conversion terms. The difference between initial net cash and note principal is an immediate financing cost before considering additional contractual charges or dilution. A secured bridge provides resources while placing a creditor claim ahead of common equity. October loan filing

The ATM waterfall also constrains capital available for operations. The first $1 million of net ATM proceeds goes to the lender. Subsequent proceeds are allocated 80% to the lender and 20% to the company until the relevant weekly repayment is covered; for the remainder of that week the allocation is 25% to the lender and 75% to the company. Default changes the treatment to the specified 80/20 split. An ATM sale therefore cannot be assumed to add its entire net amount to operating liquidity.

The note documents set a short repayment calendar. The initial note calls for thirty weekly installments of $94,500, commencing Wednesday, October 14, 2026, with a final maturity date of May 7, 2027; thirty payments of $94,500 equal the $2.835 million original principal. While the notes are outstanding, the company must maintain a minimum cash balance of $250,000, and distributions to the company under the waterfall are further limited if the market value of the registered, freely tradeable shares available under the ATM program is less than 200% of the outstanding note principal. Maxim Group, acting as placement agent, is entitled to a cash fee of 5.0% of the gross proceeds at the initial and any additional closing, reimbursement of expenses up to $5,000, and a 5.0% fee on certain financings with investors it contacted or introduced, for twelve months after closing. By our arithmetic, assuming the 5.0% fee applies to the $2.1 million funded, the lender’s 4% fee ($84,000) and Maxim’s cash fee ($105,000) leave approximately $1.911 million before expense reimbursement and other transaction costs; that is a calculation from the contractual terms, not a reported cash balance. On an event of default, outstanding principal increases to 120% and bears default interest at 19% per annum, compounded daily. The company may prepay without penalty, and full repayment within 45 days of funding, absent a default, reduces the repayment amount to 1.29 times the funded amount, less weekly installments already paid. October 9 note · Loan filing

The Q2 filing reports an amended Maxim ATM on July 27 with approximately $7,901,383 covered under the dated supplement and I.B.6 limits. That historical amount is issuance capacity, rather than a remaining October balance. The July 30 warrant inducement produced approximately $2.67 million gross from exercise of 1,702,362 warrants at $1.571, alongside 3,404,724 new warrants at $1.56. Those new claims are part of the financing cost. Subsequent events

The August 24 S-3 registers resale of underlying shares. Resale proceeds belong to selling holders; any proceeds from cash warrant exercise would be a distinct company financing event subject to the terms and approvals. Counting all registered resale value as company cash would overstate available funding. Resale registration

The first-half cash-flow statement quantifies the completed financing bridge. Net financing inflows were $7.075 million: approximately $4.335 million from ATM issuance and $2.740 million from private-placement and warrant-related proceeds. Nevertheless, cash fell by approximately $8.235 million, from $11.885 million at the beginning of the year to $3.650 million at June 30. The financing inflow helped support spending, but did not reverse the cash decline. Cash-flow statement

That relationship makes the pace of commercialization financially consequential. A slower regulatory response or slower customer adoption extends the period in which financing must support expenses. Conversely, recurring sales can gradually reduce the gap, provided their gross contribution exceeds the incremental cost of supplying and supporting customers. A placement announcement changes resources when the transaction closes; a platform milestone changes the economic outlook only to the extent that it improves the route to paid demand.

The Q2 filing reports financing activity from a private placement, warrant exercises and ATM issuance. Those transactions affect both resources and ownership. A financing analysis needs to distinguish the cash obtained during the reported period from the potential capacity of a continuing program. Financing notes

An ATM program may provide flexibility, but proceeds depend on actual sales and market conditions. A stated capacity is not the same as cash on the balance sheet. The amount raised, costs, shares issued and remaining capacity matter individually.

A private placement has its own terms. The gross amount is different from net cash after expenses. Associated warrants or other securities can create additional future claims. The economic assessment should include the full structure rather than only the headline financing amount.

Warrant proceeds are conditional on exercise. An outstanding warrant may create a possible source of cash and a possible increase in shares. Whether that source is available depends on its terms, the holder’s decision and other conditions. It cannot be added to cash automatically.

Funding can be valuable when it enables a milestone that improves the business. Its shareholder cost depends on the ownership issued and the value created by the funded work. The relevant question is the quality of that exchange, not whether dilution exists in isolation.

The company needs enough capital to support an executable commercial and regulatory sequence. If financing arrives in small increments, management may have to adjust priorities repeatedly. If the terms become more difficult, the per-share outcome can deteriorate even while the underlying product work continues.

15 Capital structure: comparable numbers require comparable denominators

The September 21 preliminary proxy proposes a further reverse split within a 1:2–1:50 range, subject to shareholder approval and board discretion within twelve months of the special meeting. It also seeks approval for exercise of the 3,404,724 new $1.56 warrants issued August 3 under the July 30 agreement. The preliminary special-meeting date is blank. The January split is historical; this later split is a proposal. Preliminary proxy

Finviz’s delayed October 13 data showed a 50.54% decline over three months, alongside a 10.95% one-month gain. Reported average daily volume was 332,980 shares. The shorter recovery and the larger quarterly decline can coexist because they cover different windows. Neither is evidence that the financing requirement has disappeared. Market data

The quarterly filing states that share and per-share figures were adjusted for the one-for-thirty reverse split effective January 1, 2026. This matters when comparing historical prices, losses per share and share counts. A comparison needs consistent treatment of the split. Per-share note

Ownership filings add a dated view of larger holders. In a Schedule 13G filed August 14, 2026, Armistice Capital, LLC and Steven Boyd reported beneficial ownership of 559,706 shares, or 9.99% of the class, as of June 30, 2026, with the shares held directly by Armistice Capital Master Fund Ltd. In a Schedule 13G/A filed August 10, Jane Street Group, LLC reported 89,240 shares, or 1.7%, as of the same date, made up of positions held by two subsidiaries. A Schedule 13G is a passive-ownership disclosure at its event date rather than a report of a new purchase, and both positions predate the July warrant inducement and the October loan, so neither describes current ownership. Armistice 13G · Jane Street 13G/A

A reverse split changes the number of shares and the price per share mechanically. It does not create cash or improve product economics by itself. The business still needs to address the factors that determine demand, expenses and financing.

Additional issuance changes the denominator again. The weighted-average share count used in a quarterly earnings calculation is different from the shares outstanding at a particular date. A valuation or ownership calculation should use the measure appropriate to its purpose.

Potentially dilutive securities create another layer. Options, warrants and other rights can affect the future ownership structure, subject to their terms. Securities excluded from a diluted loss-per-share calculation can still be economically relevant to a future per-share assessment.

Listing requirements can influence financing and corporate decisions, but compliance is not a substitute for operating progress. Maintaining a listing preserves access to a trading venue. A sustainable enterprise depends on the commercial and financial result.

The capital-structure discussion therefore belongs in the company’s core analysis. A product or platform can become more valuable while the ownership attributable to each existing share changes. Both sides of that outcome need to be visible.

16 Competition: customers buy a complete testing solution

Diagnostic competition is not simply a comparison of scientific platforms. Customers buy a testing workflow that includes performance, speed, usability, support, supply and cost. A technically capable system needs a practical reason to displace or complement existing alternatives.

A centralized laboratory can offer scale and established processes. A decentralized platform may offer a faster or more accessible result. Other rapid-testing approaches may have different information, costs and operational requirements. The useful comparison depends on the setting.

Distribution and service can be meaningful competitive factors. A customer may prefer a supplier with reliable consumable availability and a clear response to technical problems. A smaller company must demonstrate that it can provide those capabilities directly or through partners.

Switching costs can work in both directions. A good platform can become embedded in a customer workflow, supporting retention. The initial switch can nevertheless require training, process changes and investment, which can slow adoption.

The most persuasive differentiation would be an authorized test that provides useful information within a reliable and economical workflow. That position is stronger than a broad claim about platform sensitivity or a large addressable market without a customer-level justification.

17 Manufacturing, quality and support: scaling the operating promise

A diagnostic product must be reproducible. Manufacturing variability, reagent stability, instrument reliability and quality control can affect performance. Scaling a platform therefore involves disciplined processes as well as additional production volume.

Supply reliability influences adoption. A customer that builds a workflow around a test needs confidence that consumables will remain available. Inventory, lead times and distribution have direct consequences for both customer trust and working capital.

Quality systems also create ongoing costs. Validation, documentation, change control and appropriate oversight are part of the operating structure. Those requirements should be considered when assessing the margin available from future revenue.

Support can be especially important in decentralized settings. Users need clear instructions and a way to address failures or uncertainty. The company must decide which responsibilities it retains and which are handled through partners or distributors.

A successful scale-up would connect product authorization, manufacturing readiness and customer support. Weakness in any of those areas can constrain the commercial value of the others. The financial result depends on delivering the complete solution consistently.

18 Leadership and the discipline of prioritization

The September 4 filing reports Brian Brown’s departure as CFO effective September 2. Daniel Bohrer became principal financial officer and principal accounting officer that day. Those are the responsibilities assigned in the filing. The annual meeting reconvened on October 14 without a quorum and was not adjourned again; the company intends to put its proposals to a future special meeting. Leadership filing · Annual meeting filing

Dwight Egan is identified as chief executive in the Q2 results. The company has several development and commercial initiatives, making prioritization an important management responsibility. The useful assessment is how resources and operating decisions advance the most credible paths to a sustainable business. Management discussion

The Q2 results also reported the appointment of Wes Lindsey, Ph.D., MBA, as Chief Scientific Officer, to lead the company’s scientific and regulatory strategy, including FDA submissions and continued expansion of the Co-Dx product pipeline. With a 510(k) and a CLIA waiver application under review, that role sits directly on the company’s nearest regulatory milestone. Q2 results

A broad platform can create many potential applications. Pursuing them all with equal urgency can spread a small organization too thinly. A focused sequence may be more valuable when capital and support resources are limited.

Priorities should connect with milestones. Regulatory work, manufacturing and commercial demand need to advance in an order that the company can fund and execute. Management can improve clarity by explaining how each activity contributes to that sequence.

Communication quality is part of execution. A useful announcement distinguishes an application, authorization, evaluation, installation and revenue event. Precise descriptions help investors understand which uncertainty has been reduced and which remains.

The key operating discipline is to build a repeatable business from selected opportunities. Scientific breadth is useful when it supports that objective. The measure of leadership is the company’s progress in converting it into appropriate products, customers and economics.

19 Valuation: commercialization assumptions dominate a simple multiple

A revenue multiple applied to CODX’s current sales would capture only a small part of the platform story. A valuation based mainly on potential future applications would introduce substantial clinical, regulatory and commercial assumptions. A useful framework needs to show both the present business and the uncertainty of the transition.

The first layer is current contribution. Existing revenue, gross profit and operating expense describe the scale of the business already being delivered. This layer also identifies how much support is required from financing.

The second layer is the regulatory and commercial opportunity. It includes the products that may become authorized, the customers that may adopt them and the recurring use they may generate. Each assumption needs an appropriate development and implementation path.

The third layer is the capital required to reach that path. A future product opportunity has less value to existing shareholders if reaching it requires a large increase in ownership claims. Financing terms and timing are therefore central valuation inputs.

The fourth layer is execution. Manufacturing, distribution, support and retention determine how much of the commercial opportunity becomes economic contribution. A model that assumes these functions appear automatically can overstate the platform’s value.

The framework is useful without a mechanical target price. It identifies the factors that can change the business assessment: authorization, customer use, margins, expenses and funding. Those observable developments should carry more weight than an unsupported forecast of market share.

20 Milestones: which events reduce which uncertainty

A regulatory decision reduces uncertainty about permitted use. It does not determine customer demand. A successful clinical or analytical evaluation supports a performance claim, but it does not supply the working capital needed for a rollout. An installation advances implementation, but it does not prove durable utilization.

The company benefits when those milestones form a coherent sequence. Evidence supports a review. Authorization supports a commercial plan. Supply and support enable implementation. Repeat use creates revenue. Revenue and operating discipline improve the funding position.

A milestone is more valuable when it resolves a constraint that was limiting the next step. For example, a defined authorized use can allow the company to focus manufacturing and distribution. A stable customer relationship can help make demand more predictable. Completed financing can allow an executable development plan to proceed.

The timing of milestones also matters. A delay can increase the resources required to reach the next stage. The same eventual product result can have different per-share implications depending on the capital consumed along the way.

The practical monitoring sequence is therefore specific: agency decisions and terms, reliable implementation, recurring demand, reported contribution and completed financing. A company-wide narrative becomes more credible as the evidence connecting those steps strengthens.

21 Risks and falsifiers: the central commercialization test

The regulatory risk is that the review takes longer, requires additional work or produces a narrower commercial scope than assumed. That would change the timing, cost or size of the rollout. The relevant evidence is the agency’s decision and the company’s disclosed response.

The commercial risk is that installations do not generate enough recurring use. Customer counts can grow while test volume remains modest. Weak retention, small repeat orders or expensive support would limit the value of the installed base.

The financial risk is that capital needs exceed the resources available on acceptable terms. The quarterly filing makes the financing dependency clear. A development plan that assumes no further financing would be inconsistent with that operating position.

The execution risk is that production, supply or support fails to meet the requirements of customers. A platform can be scientifically capable while facing operating constraints. Those constraints may increase costs or slow adoption.

The portfolio risk is that too many initiatives compete for limited resources. International development, environmental testing and point-of-care diagnostics may each be useful, but the company needs priorities that fit its funding and organizational capacity.

The per-share risk is that financing and compensation claims expand faster than the value created by commercialization. Business progress alone does not settle that question. The number and terms of securities issued remain part of the economic outcome.

The strongest evidence against a contrary reading would be authorized products, stable customer use, a growing recurring contribution, controlled expenses and funding that supports the operating plan. The central test is whether Co-Diagnostics can turn its platform and implementation milestones into a financed, repeatable diagnostic and environmental-testing business.

22 The financial bridge between development and repeat revenue

The reported quarter illustrates the scale of the transition. The company has been investing in products, evidence, infrastructure and customer implementation while current revenue remains limited. That makes the relationship between development spending and the next commercial milestones especially important.

An instrument business can encounter a period in which costs precede consumable demand. Manufacturing preparation, regulatory work, training and distribution may be required before a customer produces repeat orders. A funded plan needs to accommodate that period, rather than assume revenue appears as soon as development is complete.

The quality of the bridge depends on the value of the work being funded. Spending that resolves a specific regulatory or customer constraint can improve the path to recurring sales. Spending across many loosely connected opportunities may be harder to convert into a measurable business result.

Financial discipline therefore has both a cost and a strategic dimension. Reducing expense can preserve cash, but the company also needs to protect the activities essential to useful authorization and implementation. The objective is a sequence of milestones that fits the resources available.

A stronger bridge would become visible through recurring product demand and improving gross profit, alongside financing that allows the company to execute rather than merely postpone a funding problem. That is the economic connection between a plausible technology platform and a more resilient listed business.

Primary sources

• Q2 2026 Form 10-Q
• Q2 results, August 13
• Respiratory 510(k) submission, August 6
• Vector Smart installation, October 8
• ReadyGo collaboration, September 16
• Tuberculosis study in India, July 22
• Company website

Frequently asked questions

What does Co-Diagnostics do? It develops molecular testing reagents, related technology and PCR-platform applications, with diagnostic and environmental-monitoring activities.

Is a 510(k) submission the same as clearance? No. Submission begins or advances a review process. Clearance requires an agency decision concerning the particular device and proposed use.

What is the role of the CLIA waiver application? It concerns the conditions for use in waived testing settings. It is distinct from the device-clearance decision.

Do Vector Smart installations prove a clinical test is authorized? No. Environmental surveillance and human clinical diagnosis have different purposes and regulatory requirements.

Why is recurring use important? An installed system creates an opportunity for consumable demand. Continued testing determines its ongoing financial contribution.

Is the company’s cash position current indefinitely? No. The reported amount is a June 30 balance. Subsequent spending, financing and obligations can change it.

Does a reverse split improve product economics? It changes shares and per-share figures mechanically. Demand, costs and the operating plan remain separate business questions.

What would strengthen the company assessment? Useful agency decisions, repeat customer demand, improving gross profit, operating discipline and completed financing would reinforce the commercialization path.

This analysis is educational and informational. It is not investment advice, a recommendation to buy or sell securities, or guidance on diagnostic or treatment decisions. Readers should conduct their own research and consult qualified professionals where appropriate.